VYNE Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- VYNE Therapeutics's estimated annual revenue is currently $21.9M per year.
- VYNE Therapeutics's estimated revenue per employee is $201,000
Employee Data
- VYNE Therapeutics has 109 Employees.
- VYNE Therapeutics grew their employee count by -50% last year.
VYNE Therapeutics's People
| Name | Title | Email/Phone |
|---|
VYNE Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is VYNE Therapeutics?
VYNE Therapeutics' mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
keywords:N/A
N/A
Total Funding
109
Number of Employees
$21.9M
Revenue (est)
-50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
VYNE Therapeutics News
VYNE Therapeutics reported sales of $4.12 million in the same quarter last year, which indicates a negative year-over-year growth rate of 86.7%.
VYNE Therapeutics reported sales of $4.12 million in the same quarter last year, which indicates a negative year-over-year growth rate of 86.7%.
VYNE Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would suggest a positive year-over-year growth...
VYNE Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would suggest a positive year-over-year growth...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 109 | 11% | N/A |
#2 | $5.5M | 109 | 4% | N/A |
#3 | $19.6M | 109 | 6% | N/A |
#4 | $29.4M | 109 | 7% | N/A |
#5 | $17.8M | 109 | -53% | N/A |